Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.
Diabetologia. 2013 May;56(5):965-72. doi: 10.1007/s00125-013-2841-0. Epub 2013 Feb 3.
AIMS/HYPOTHESIS: We carried out a systematic review of clinical studies investigating glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes and non-diabetic controls and performed meta-analyses of plasma total GLP-1 concentrations during an OGTT and/or meal test.
Random effects models for the primary meta-analysis and random effects meta-regression, subgroup and regression analyses were applied.
Random effects meta-analysis of GLP-1 responses in 22 trials during 29 different stimulation tests showed that patients with type 2 diabetes (n = 275) and controls without type 2 diabetes (n = 279) exhibited similar responses of total GLP-1 (p = NS) as evaluated from peak plasma concentrations (weighted mean difference [95% CI] 1.09 pmol/l [-2.50, 4.67]), total AUC (tAUC) (159 pmol/l × min [-270, 589]), time-corrected tAUC (tAUC min⁻¹) (0.99 pmol/l [-1.28, 3.27]), incremental AUC (iAUC) (-122 pmol/l × min [-410, 165]) and time-corrected iAUC (iAUC min⁻¹) (-0.49 pmol/l [-2.16, 1.17]). Fixed effects meta-analysis revealed higher peak plasma GLP-1 concentrations in patients with type 2 diabetes. Subgroup analysis showed increased responses after a liquid mixed meal test (peak, tAUC and tAUC min⁻¹) and after a 50 g OGTT (AUC and tAUC min⁻¹), and reduced responses after a solid mixed meal test (tAUC min⁻¹) among patients with type 2 diabetes. Meta-regression analyses showed that HbA1c and fasting plasma glucose predicted the outcomes iAUC and iAUC min⁻¹, respectively.
CONCLUSIONS/INTERPRETATION: The present analysis suggests that patients with type 2 diabetes, in general, do not exhibit reduced GLP-1 secretion in response to an OGTT or meal test, and that deteriorating glycaemic control may be associated with reduced GLP-1 secretion.
目的/假设:我们对研究 2 型糖尿病患者和非糖尿病对照者胰高血糖素样肽-1(GLP-1)分泌的临床研究进行了系统评价,并对口服葡萄糖耐量试验(OGTT)和/或餐试期间的血浆总 GLP-1 浓度进行了荟萃分析。
应用主要荟萃分析和随机效应荟萃回归、亚组和回归分析的随机效应模型。
22 项试验中 29 项不同刺激试验的随机效应荟萃分析显示,2 型糖尿病患者(n=275)和无 2 型糖尿病对照者(n=279)的总 GLP-1 反应相似(p=NS),从血浆峰值浓度评估(加权均数差[95%CI]1.09pmol/l[-2.50,4.67])、总 AUC(tAUC)(159pmol/l×min[-270,589])、时间校正 tAUC(tAUCmin-1)(0.99pmol/l[-1.28,3.27])、增量 AUC(iAUC)(-122pmol/l×min[-410,165])和时间校正 iAUC(iAUCmin-1)(-0.49pmol/l[-2.16,1.17])。固定效应荟萃分析显示,2 型糖尿病患者的血浆 GLP-1 峰值浓度更高。亚组分析显示,液体混合餐试验后(峰值、tAUC 和 tAUCmin-1)和 50gOGTT 后(AUC 和 tAUCmin-1)反应增加,而固体混合餐试验后(tAUCmin-1)反应减少。荟萃回归分析显示,HbA1c 和空腹血糖分别预测 iAUC 和 iAUCmin-1 的结果。
结论/解释:本分析表明,一般来说,2 型糖尿病患者在 OGTT 或餐试时 GLP-1 分泌不会减少,血糖控制恶化可能与 GLP-1 分泌减少有关。